NCT04914832View on ClinicalTrials.gov

Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death

PHASE4CompletedINTERVENTIONAL
Enrollment

75,012

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
COVID-19Pneumonia, Viral
Interventions
BIOLOGICAL

AZD1222

AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.

Trial Locations (1)

Unknown

Vaccination Center, Mbabane

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Shabir Madhi

OTHER

NCT04914832 - Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death | Biotech Hunter | Biotech Hunter